Clinical Trials Browser

HER2-positive Breast Cancer × Fluorodeoxyglucose F18 × 90 days × Clear all

NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Phase 1/2 Withdrawn

HER2-positive Breast Cancer